Background Resistance burden varies widely among WHO regions, and the potential impact
of new antibiotics differs in addressing the WHO's critical priority pathogens' resistance …

Acinetobacter baumannii is one of the most common multidrug-resistant pathogens causing
nosocomial infections. The prevalence of multidrug-resistant A. baumannii infections is …

ABSTRACT SPR206 is a novel polymyxin derivative with potent in vitro activity against
susceptible and multidrug-resistant strains of Acinetobacter baumannii, Pseudomonas …

With the rising incidences of antimicrobial resistance (AMR) and the diminishing options of
novel antimicrobial agents, it is paramount to decipher the molecular mechanisms of action …

Healthy state is priority in today's world which can be achieved using effective medicines.
But due to overuse and misuse of antibiotics, a menace of resistance has increased in …

Infections due to Acinetobacter spp. are among the most difficult to treat. Most are resistant to
standard antibiotics, and there is difficulty in distinguishing colonizers from pathogens. This …

Thanatin is a β-hairpin antimicrobial peptide cyclised by a single disulfide bond that has
shown potent broad-spectrum activity towards bacterial and fungal pathogens. Towards …

Objectives Polymyxins are a vital class of antibiotics used to combat multidrug-resistant
Gram-negative bacteria. However, their use is limited due to potential nephrotoxicity and the …

ABSTRACT SPR206 is a next-generation polymyxin being developed for the treatment of
multidrug-resistant (MDR) Gram-negative infections. This Phase 1 bronchoalveolar lavage …

MRX-8 is a novel polymyxin for carbapenem-resistant Gram-negative infections that has
been recently evaluated in Phase I clinical trials. Herein, its pharmacokinetics (PK) and …